' x='0' y='0' width='795' height='447'%3E%3C/rect%3E%3Ctext id='Loading-Preview' font-family='AvenirNext-Bold, Avenir Next' font-size='42' font-weight='bold' fill='%23FFFFFF'%3E%3Ctspan x='228.715' y='211'%3ELoading Preview%3C/tspan%3E%3C/text%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Description | Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria. |
h1 tags | Your page doesn't have H1 tags. |
h2 tags | Corporate Responsibility at Alnylam Challenge Accepted RNAi Therapeutics Access to our medicines Our Robust Pipeline Alnylam Named to Bloomberg’s Gender-Equality Index LATEST NEWS OUR FOCUS ON PATIENTS OUR PIPELINE & PLATFORMS CAREERS @ALNYLAM SIGN UP FOR EMAIL UPDATES About Alnylam Our Science Our Products Our Pipeline Medical Professionals Patients Investors Careers |
Site Speed | 1.0576980113983 |
Alexa Rank: |
0 |
Site's Traffic |
|
| Host | Type | Class | TTL | Target |
| alnylam.com | SOA | IN | 299 | |
| alnylam.com | NS | IN | 299 | dns2.easydns.net |
| alnylam.com | NS | IN | 299 | dns1.easydns.com |
| alnylam.com | NS | IN | 299 | dns3.easydns.org |
| alnylam.com | MX | IN | 599 | us-smtp-inbound-2.mimecast.com |
| alnylam.com | MX | IN | 599 | us-smtp-inbound-1.mimecast.com |
| alnylam.com | A | IN | 299 | |
| alnylam.com | TXT | IN | 299 | |
| alnylam.com | TXT | IN | 299 | |
| alnylam.com | TXT | IN | 299 | |
| alnylam.com | TXT | IN | 299 | |
| alnylam.com | TXT | IN | 299 | |
| alnylam.com | TXT | IN | 299 | |
| alnylam.com | TXT | IN | 299 | |
| alnylam.com | TXT | IN | 299 | |
| alnylam.com | TXT | IN | 299 | |
| alnylam.com | TXT | IN | 299 | |
| alnylam.com | TXT | IN | 299 | |
| alnylam.com | TXT | IN | 299 | |
| alnylam.com | TXT | IN | 299 |